ArticleFrontiers in oncology2026
Real-world efficacy and safety of PD-1 inhibitors in patients living with HIV and cancer: a retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Programmed cell death protein 1 (PD-1) inhibitors have established a cornerstone in cancer therapy; however, there remains a lack of data regarding their use in people living with human immunodeficiency virus (HIV) infection (PWH), especially in patients with low CD4 Methods: From January 2022 to December 2024, patients diagnosed with cancer and treated with PD-1 inhibitors (camrelizumab, sintilimab, or tislelizumab) were enrolled. The included population was divided into an HIV-positive group and an HIV-negative group based on HIV status. Demographic details, clinical data, and cancer status were collected. Using propensity score matching (PSM) to adjust for baseline imbalances, we compared median progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (TRAEs) between the two groups. Cox regression analysis was conducted to evaluate the influence of multiple variables on treatment response. Results: From 90 enrolled patients (70 HIV-positive, 20 HIV-negative), PSM selected 56 (37 HIV-positive, 19 HIV-negative) for final analysis. The ORR and DCR were comparable between the HIV-positive and HIV-negative groups (16.2% vs. 15.8% and 51.4% vs. 47.4%, respectively). Median PFS was 11.5 months (95% CI: 6.8-16.2) for the HIV-positive group and 16.9 months (95% CI: Not evaluated (NE)-40.4) for the HIV-negative group. For the lung cancer subgroup, the ORR and DCR were 23.5% and 70.6% among 17 HIV-positive patients vs. 30.0% and 50.0% among 10 HIV-negative patients. The respective median PFS was 14.5 months (95% CI: 4.9-24.2) and 17.2 months (95% CI: NE-36.0). Multivariable Cox regression analysis confirmed that HIV status was not independently associated with PFS in the overall cohort. Among the four patients with low baseline CD4 Conclusion: This retrospective study indicated that PD-1 inhibitors are effective and generally well tolerated in PWH with concurrent malignancies. HIV status was not an independent prognostic factor for treatment outcomes, and robust immune restoration was achievable even in patients with advanced baseline immunosuppression. Although severe (grade ≥ 3) TRAEs and treatment discontinuations occurred exclusively within the HIV-positive cohort, overall toxicity rates remained low. Larger prospective studies are required to further validate these findings in patients with low CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.